1. Clinical & Scientific Overview
Gentamicin Sulfate (TIP-MED-000335, Reference Code [8.23]-C65) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Aminoglycoside 30S Ribosomal Bactericidal Antibiotics (Schedule H | NLEM 2022 | HIGH-ALERT).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [8.23] (Amikacin Sulfate & Gentamicin Sulfate). Representative Indian Market Examples (Edition 2.7 Ch 08 [8.23], p. 104): Amikacin: Mikacin (Aristo), Amicin (Zydus), Amitax (Alkem). Gentamicin: Garamycin (MSD), Genticyn (Abbott) — Strengths & Dosage Forms: Amikacin Vials: 100 mg/2mL, 250 mg/2mL, 500 mg/2mL. Gentamicin Vials: 40 mg/mL (2 mL = 80 mg); Paediatric: 10 mg/mL; Eye/Ear Drops: 0.3%
Amikacin Vials: 100 mg/2mL, 250 mg/2mL, 500 mg/2mL. Gentamicin Vials: 40 mg/mL (2 mL = 80 mg); Paediatric: 10 mg/mL; Eye/Ear Drops: 0.3%
3. Mechanism of Action & Pharmacodynamics
Aminoglycoside 30S Ribosomal Bactericidal Antibiotics (Schedule H | NLEM 2022 | HIGH-ALERT) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Aminoglycoside 30S Ribosomal Bactericidal Antibiotics (Schedule H | NLEM 2022 | HIGH-ALERT) for Severe Gram-negative hospital sepsis, complicated pyelonephritis/urosepsis, febrile neutropenia, infective endocarditis (Gentamicin synergy), neonatal sepsis, and NTM/MDR-TB (Amikacin).
4. Therapeutic Indications & Evidence-Supported Uses
- Severe Gram-negative hospital sepsis, complicated pyelonephritis/urosepsis, febrile neutropenia, infective endocarditis (Gentamicin synergy), neonatal sepsis, and NTM/MDR-TB (Amikacin)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: EXTENDED-INTERVAL ONCE-DAILY DOSING (maximises Cmax/MIC peak killing and reduces nephrotoxicity!): Amikacin: 15 mg/kg IV/IM Once Daily (Max 1.5 g/d). Gentamicin: 5–7 mg/kg IV Once Daily (Endocarditis synergy: 3 mg/kg/d)
Administration & Meal Timing: Infuse IV dose in 100 mL 0.9% NaCl or D5W over 30–60 minutes (never give undiluted rapid IV bolus — causes neuromuscular respiratory paralysis!) | Once Daily (q24h) in normal renal function; extend interval to q36h or q48h in CKD
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [8.23].
Renal: 99% excreted unchanged by glomerular filtration — mandatory Cockcroft–Gault CrCl calculation and interval extension (q36–48h) + TDM trough (<1 mcg/mL for Gentamicin, <4–5 mcg/mL for Amikacin) in any renal impairment!
Renal: 99% excreted unchanged by glomerular filtration — mandatory Cockcroft–Gault CrCl calculation and interval extension (q36–48h) + TDM trough (<1 mcg/mL for Gentamicin, <4–5 mcg/mL for Amikacin) in any renal impairment!
Renal: 99% excreted unchanged by glomerular filtration — mandatory Cockcroft–Gault CrCl calculation and interval extension (q36–48h) + TDM trough (<1 mcg/mL for Gentamicin, <4–5 mcg/mL for Amikacin) in any renal impairment!
7. Contraindications, Precautions & High-Risk Warnings
- BOXED WARNINGS — NEPHROTOXICITY, IRREVERSIBLE OTOTOXICITY & NEUROMUSCULAR BLOCKADE: Contraindicated in Myasthenia Gravis (precipitates crisis!), pregnancy (congenital bilateral deafness in foetus!), and perforated tympanic membrane (for ear drops!). Physically incompatible in same IV bag with Beta-Lactams!
Key Clinical Precautions: Renal: 99% excreted unchanged by glomerular filtration — mandatory Cockcroft–Gault CrCl calculation and interval extension (q36–48h) + TDM trough (<1 mcg/mL for Gentamicin, <4–5 mcg/mL for Amikacin) in any renal impairment!
8. Adverse Effects Profile
- Reversible non-oliguric rise in serum creatinine (acute tubular necrosis in 5–15%)
- Irreversible Cochlear Ototoxicity (high-frequency sensorineural deafness, tinnitus) and Vestibular Toxicity (oscillopsia, ataxia, disequilibrium), acute renal failure, apnoea/respiratory paralysis
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Additive nephrotoxicity with Vancomycin, Amphotericin B, NSAIDs, Cisplatin, Contrast dye, and Cyclosporine/Tacrolimus; Loop diuretics (Furosemide/Torsemide IV) markedly increase irreversible cochlear deafness!; potentiates Vecuronium/Rocuronium/Magnesium Sulfate neuromuscular block
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [8.23].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Report any ringing in the ears (tinnitus), muffled hearing, or dizziness/balance loss immediately (hearing loss can be permanent if the injection is not stopped at the first sign!); maintain good hydration
- Meal & Clock Timing Instruction: Infuse IV dose in 100 mL 0.9% NaCl or D5W over 30–60 minutes (never give undiluted rapid IV bolus — causes neuromuscular respiratory paralysis!) (Once Daily (q24h) in normal renal function; extend interval to q36h or q48h in CKD)
- Missed Dose Protocol: Inpatient scheduled parenteral dosing
- Geriatric Dispensing Pearl: High risk of rapid nephrotoxicity and permanent vestibular/hearing loss in older adults; avoid if beta-lactam monotherapy is adequate
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Amikacin Vials: 100 mg/2mL, 250 mg/2mL, 500 mg/2mL. Gentamicin Vials: 40 mg/mL (2 mL = 80 mg); Paediatric: 10 mg/mL; Eye/Ear Drops: 0.3%
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.26] Fosfomycin Trometamol — Phosphonic Acid Epoxide Cell-Wall (MurA) Synthesis Inhibitor — Si
- [8.27] Vancomycin & Teicoplanin (Glycopeptide Reserve Antibiotics) — Glycopeptide Cell-Wall D-Ala-D-Ala Peptidoglycan Inhibitors — ICM
- [8.2]-C53 Potassium Clavulanate (Co-amoxiclav) — Aminopenicillin + Irreversible Beta-Lactamase Inhibitor Combinati
- [8.8]-CMP54 Norfloxacin IP — Second-Generation Fluoroquinolone Antibiotic (Bactericidal DNA Gy
